TC BioPharm (TCBP) has signed a non-binding letter of intent (LoI) to acquire an ophthalmic pharmaceutical company focused on commercialising intraocular pressure-minimising therapies for individuals with glaucoma and ocular hypertension.
The target company owns a US Food and Drug Administration (FDA)-approved one-time-a-day eye drop that minimises intraocular pressure, and a development-stage asset pipeline in ophthalmology indications.
Go deeper with GlobalData
The approved product is being distributed to 300 physicians for a 90-day treatment sample, with a full commercial launch anticipated shortly.
TCBP will buy the company through an all-stock transaction.
The acquisition aligns with TC BioPharm’s mergers and acquisitions strategy, which seeks to broaden its therapeutic platform and incorporate later-stage assets that quickly add value.
TC BioPharm CEO Bryan Kobel stated: “TCBP expects to execute the binding letter of intent in the next two to three weeks and close the acquisition formally in the third quarter of 2025. We are extremely pleased to be acquiring this high-growth company in an area of strong institutional investor and pharma interest, with over $10bn in mergers and acquisitions and funding in the last 12 to 18 months.
“We believe they will diversify and de-risk our platform while advancing our mission of targeting promising novel treatments in underserved markets and better positioning the company for enhancing long-term future shareholder value.”
TCBP focuses on the discovery, development and commercialisation of gamma-delta T-cell therapies for treating cancer, with human efficacy data available in acute myeloid leukaemia.
In August 2024, TCBP received a patent grant from the European Patent Office. The patent covers the use of modified gamma-delta cells in treating cancer and viral indications.
